A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke

Stroke; a Journal of Cerebral Circulation
K W Muir, K R Lees

Abstract

Magnesium ions act as endogenous vasodilators of the cerebral circulation and act pharmacologically as noncompetitive antagonists of the N-methyl-D-aspartate receptor by virtue of their role as endogenous voltage-sensitive blockers of the ion channel. The preclinical efficacy of magnesium has been demonstrated in standard models of stroke. Sixty patients were randomized to magnesium sulfate (8 mmol IV over 15 minutes and 65 mmol over 24 hours) or placebo within 12 hours of clinically diagnosed middle cerebral artery stroke. Pulse, blood pressure, and serum magnesium levels were monitored. Primary outcome was death or significant functional impairment (Barthel Index score < 60) at 3 months. Magnesium was well tolerated, with no significant adverse effects and no change in blood pressure or pulse rate. Laboratory and electrocardiographic variables did not differ significantly between placebo- and magnesium-treated groups. Serum magnesium rose from 0.76 mmol/L to 1.42 mmol/L over 24 hours and remained significantly higher than in the placebo group at 48 hours. Thirty percent of magnesium-treated and 40% of placebo-treated patients were dead or disabled (Barthel Index score < 60) at 3 months (P = .42). There was a decrease in the n...Continue Reading

References

Sep 11, 1992·American Journal of Obstetrics and Gynecology·M A Belfort, K J Moise
Jul 1, 1991·British Journal of Clinical Pharmacology·K L Woods
Nov 1, 1991·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Y IzumiJ Seylaz
Feb 5, 1990·Neuroscience Letters·J W McDonaldM V Johnston
May 1, 1990·American Journal of Obstetrics and Gynecology·B M Sibai
Jun 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S Finkbeiner, C F Stevens
Mar 20, 1989·Brain Research·T K McIntoshA I Faden
Feb 1, 1985·British Journal of Pharmacology·N L Harrison, M A Simmonds
Nov 3, 1988·The New England Journal of Medicine·R S Goldman, S M Finkbeiner
Dec 16, 1987·Biochemical and Biophysical Research Communications·R VinkA I Faden
Jul 1, 1984·American Heart Journal·L T Iseri, J H French
Apr 2, 1994·Lancet·A P Wilson
Nov 28, 1993·Biochimica Et Biophysica Acta·F A SchanneP K Stanton

❮ Previous
Next ❯

Citations

Mar 9, 2005·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Dean D BellDavid Zygun
Dec 21, 2000·Current Atherosclerosis Reports·S H AhmedC Y Hsu
Mar 20, 2002·Current Neurology and Neuroscience Reports·H L Lutsep, W M Clark
May 24, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Preeti Sahota, Sean I Savitz
May 4, 2001·Brain Research. Developmental Brain Research·R C KruegerN B Schwartz
May 24, 2003·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Erkan KaptanogluYamac Taskin
May 3, 2000·British Journal of Haematology·D R Powars
Oct 1, 1996·Journal of Clinical and Experimental Neuropsychology·T A NovackW T Jackson
Aug 7, 1998·Neuroreport·W S van der HelR M Dijkhuizen
Dec 1, 1996·Journal of Clinical Pharmacy and Therapeutics·A G Dyker, K R Lees
Mar 21, 2009·Stroke; a Journal of Cerebral Circulation·Chelsea S KidwellUNKNOWN MR IMAGES Investigators
Apr 27, 2013·Experimental & Translational Stroke Medicine·Thomas WestermaierRalf-Ingo Ernestus
Nov 21, 2001·Current Controlled Trials in Cardiovascular Medicine·Andrew Bradford, Kennedy Lees
Jan 22, 2003·Neurosurgery·Walter M van den BerghGabriël J E Rinkel
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Lise A Labiche, James C Grotta
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Shang-Der ChenChung Y Hsu
May 16, 2009·Journal of Neurosurgery. Spine·Diana Barrett WisemanChristopher I Shaffrey
Oct 8, 2009·Pakistan Journal of Biological Sciences : PJBS·B Habibi-AslS Mohammadi
Jan 1, 2009·Neurology International·Mohamed BarbarawiShboul Abdullah
Aug 25, 2012·Annals of Indian Academy of Neurology·Harpreet SinghIshwar Singh
Feb 14, 2004·Lancet·K W MuirUNKNOWN Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators
Jul 17, 1998·Anesthesiology·M N Gomez
Mar 31, 1999·Current Opinion in Neurology·G Devuyst, J Bogousslavsky
Apr 2, 2008·Expert Opinion on Pharmacotherapy·K JeyaseelanA Armugam
Dec 19, 2013·The Journal of Membrane Biology·Sevdegul KaradasHalit Demir
Oct 6, 2004·Best Practice & Research. Clinical Anaesthesiology·Thomas Frietsch, Jeffrey R Kirsch
May 30, 1998·Lancet·K R Lees
Aug 6, 1999·European Journal of Anaesthesiology·J E Cottrell
May 16, 2015·Current Treatment Options in Neurology·Jose Torres, Koto Ishida
Jul 4, 2012·Clinical Neurology and Neurosurgery·Daryoush AfshariMansour Rezaei
Dec 20, 2005·Neuroimaging Clinics of North America·Aneesh B SinghalMichael A Moskowitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.